Get the Stockscreener App
9.905
72.91%
-26.66
After Hours:
10.05
0.145
+1.46%
Maplight Therapeutics Inc stock is traded at $9.905, with a volume of 8.07M.
It is down -72.91% in the last 24 hours and down -70.24% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$36.56
Open:
$12.98
24h Volume:
8.07M
Relative Volume:
15.22
Market Cap:
$449.15M
Revenue:
-
Net Income/Loss:
$-161.15M
P/E Ratio:
-2.6663
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
-72.48%
1M Performance:
-70.24%
6M Performance:
-48.28%
1Y Performance:
+0.00%
1-Day Range:
$9.905
$14.50
1-Week Range:
$9.905
$38.26
52-Week Range:
$9.905
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
9.905 | 1.66B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results - Investing.com Canada
Wolfe cuts MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Canada
MapLight Therapeutics' Lead Candidate Falls Meaningfully Short In Schizophrenia (MPLT) - Seeking Alpha
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint - MarketBeat
MapLight dives despite positive data for schizophrenia drug - BioPharma Dive
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire
Maplight Therapeutics (NASDAQ:MPLT) Sets New 12-Month LowTime to Sell? - MarketBeat
MapLight Therapeutics stock holds Buy rating at TD Cowen after trial data - Investing.com Canada
Raymond James cuts MapLight Therapeutics stock price target on efficacy data - Investing.com Canada
Jefferies reiterates MapLight Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
MapLight Therapeutics (MPLT) Faces Stock Decline Despite Positiv - GuruFocus
BMO reiterates Outperform on MapLight stock after trial data By Investing.com - Investing.com Canada
Stifel reiterates MapLight Therapeutics stock rating on schizophrenia data By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
MPLT: ML-007C-MA met key efficacy and safety endpoints in Phase 2 schizophrenia trial, supporting Phase 3 plans - TradingView
Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia - marketscreener.com
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
MapLight schizophrenia drug meets phase 2 trial primary endpoint - Investing.com
MapLight Therapeutics stock tumbles 40% on trial results - Investing.com
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - The Manila Times
MapLight Therapeutics (Nasdaq: MPLT) hits key Phase 2 goal in schizophrenia - Stock Titan
MapLight Therapeutics Inc (MPLT) Cash Flow - TradingKey
MPLT|MapLight Therapeutics Inc|Price:36.560|Chg%:+1.330 - TradingKey
TradingKey - TradingKey
Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56? - Yahoo! Finance Canada
MapLight Therapeutics, Inc. Revenue Breakdown – NASDAQ:MPLT - TradingView
MAPLIGHT THERAPEUTICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $43 FROM $35 - webull.com
Canaccord raises MapLight Therapeutics price target on trial data By Investing.com - Investing.com Canada
Possible Bearish Signals With MapLight Therapeutics Insiders Disposing Stock - simplywall.st
Wall Street Analysts Are Bullish on Top NA Picks - The Globe and Mail
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by BMO Capital Markets to Strong-Buy Rating - MarketBeat
Form 4 MapLight Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
MapLight Therapeutics CSO James Woodruff sells $673k in shares for tax - Investing.com UK
MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says - marketscreener.com
BMO Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $46 - Moomoo
UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating - Moomoo
MapLight Therapeutics CEO Kroeger sells $5.4m in company stock By Investing.com - Investing.com Australia
MPLT Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
UBS raises MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Canada
MapLight Therapeutics general counsel sells $607,870 in shares By Investing.com - Investing.com South Africa
MapLight Therapeutics general counsel sells $607,870 in shares - Investing.com
MapLight Therapeutics CEO Kroeger sells $5.4m in company stock - Investing.com
BMO Capital Initiates MapLight Therapeutics at Outperform With $46 Price Target - marketscreener.com
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $46 - Moomoo
MapLight Therapeutics (MPLT) Coverage Initiated with Outperform Rating and Price Target - GuruFocus
Form 4 MapLight Therapeutics Inc For: 20 July By Investing.com - Investing.com Nigeria
Maplight Therapeutics Insider Sold Shares Worth $1,372,668, According to a Recent SEC Filing - marketscreener.com
MapLight Therapeutics (MPLT) CDO sells 36K shares via tax and plan trades - Stock Titan
MapLight Therapeutics (MPLT) CAO and interim CFO reports 36,979-share stock sale - Stock Titan
MapLight Therapeutics Insider Sold Shares Worth $5,443,722, According to a Recent SEC Filing - marketscreener.com
Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer disposes of USD 1.34 million in common shares - Bitget
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):